Clinical Trial Update: Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial of Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Sunphenon Epigallocatechin-gallate (EGCg) (epigallocatechin-gallate)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Duchenne Muscular Dystrophy | Phase 2, Phase 3 | Status: COMPLETED